Stock Market & Financial Investment News

Cubist Sivextro sales to benefit from lack of warnings, says JMP SecuritiesAfter the FDA approved Cubist's Sivextro treatment for skin infections, JMP Securities notes that the FDA did not require warnings about a number of potential serious side effects to be placed on the drug's label. The firm thinks the absence of these warnings should boost sales of the drug. It reiterates an Outperform rating on Cubist.